3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression
Assignee
Takeda Pharmaceutical Company Limited
Inventors
Tomoaki Hasui, Satoshi Mikami, Toru Yamashita, Shinji Nakamura, Shinji Morimoto, Toshihiro Imaeda, Kazuaki Takami, Masaki Daini, Hiroyuki Kakei, Minoru Nakamura, Fumie Yamaguchi, Chunxiang Wang, Sachie Takashima, Makoto Kamata, Yuya Oguro, Shuhei Ikeda
Abstract
The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).
CPC Classifications
Filing Date
2021-05-20
Application No.
17999514
Claims
27